miRNA regulation, antitumor activity, and molecular modeling by (S)-Naproxen-1,2,4-triazole compound in human Breast cancer
Journal of Research in Pharmacy, cilt.30, sa.3, ss.812-825, 2026 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 30 Sayı: 3
- Basım Tarihi: 2026
- Doi Numarası: 10.12991/jrespharm.1706713
- Dergi Adı: Journal of Research in Pharmacy
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.812-825
- Anahtar Kelimeler: MDA-MB-231, miR-133a-5p, molecular modeling, Naproxen, Bcl-2
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Erciyes Üniversitesi Adresli: Evet
Özet
This study investigated the effect of a newly synthesized original molecule with a 1,2,4-triazole with a 2-fluorophenyl ring on miRNA. (S)-Naproxen was chosen as the starting molecule for synthesis. In molecular modeling studies, compound (4a) was used to control for the Bcl-2 apoptotic marker. The primary objective was to demonstrate that the MDA-MB-231 cell line exhibited growth inhibition in a dose-dependent manner following compound treatment. The results showed that compound (4a) inhibited the motility of MDA-MB-231 cells. Compound (4a) at concentrations of 75, 150, and 300 µM significantly reduced the viability of MDA-MB-231 cells compared to the control group. IC50 value of the compound (4a) for 48 h was 57.6 µM. In our study, for the first time, miR-133a-5p was significantly up-regulated in MDA-MB-231 breast cancer cells treated with compound (4a) at different concentrations compared to the control group. As such, miR-133a-5p may play a crucial role in tumorigenesis by targeting Bcl-2 in MDA-MB-231 cells and could serve as a biomarker for therapeutic targets in breast cancer treatment.